BLFSBioLife Solutions, Inc.
Price
+50%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, nothing alarming, demanding price, growth steady, the market undecided.
We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
BioLife Solutions, Inc. (BLFS) reported revenue of $28M in Q2 2026 (quarter ended Jun 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 64% and net income of $45M (158% of revenue). For the full year FY2025, revenue was $96M (+29% year on year) and net income −$4.6M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was Product Cell Processing at $25M, 85% of the disclosed total, well ahead of Rental Revenue Evo And Thaw at 6.0%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 6, 2026At the effective time of the First Merger (the “First Merger Effective Time”), each share of BioLife’s common stock, par value $0.001 per share (“BioLife Common Stock”), issued and outstanding immediately prior to the First Merger Effective Time (other than (i) any shares that were held by BioLife in treasury or owned …Acquisition or disposition completed · Form 8-K
- Sep 9, 2026As previously disclosed, on July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Repligen Corporation, a Delaware corporation (“Repligen”), Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of …Other event · Form 8-K
- Jul 22, 2026Merger Agreement On July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among, BioLife, Repligen Corporation, a Delaware corporation (“Repligen”), Bravo Merger Sub I, Inc., a Delaware corporation and …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2025 · $29.9MThe company’s own SEC segment disclosure.
- Product Cell Processing$25.3M85%
- Rental Revenue Evo And Thaw$1.8M6%
- Rental$1.8M6%
- Product Evo And Thaw$968.0K3%
- Service Evo And Thaw$26.0K0%
- Service$26.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #18 of 21 by RyuScore